Kineta (Kineta) FCF Yield % : -255.86 (As of May. 12, 2024)

View and export this data going back to 2022. Start your Free Trial

What is Kineta FCF Yield %?

FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

As of today, Kineta's Trailing 12-Month Free Cash Flow is $-16.21 Mil, and Market Cap is $6.34 Mil. Therefore, Kineta's FCF Yield % for today is -255.86%.

The historical rank and industry rank for Kineta's FCF Yield % or its related term are showing as below:

KA' s FCF Yield % Range Over the Past 10 Years
Min: -351.57 Med: -66.53 Max: -37.19
Current: -255.86

During the past 4 years, the highest FCF Yield % of Kineta was -37.19%. The lowest was -351.57%. And the median was -66.53%.

KA's FCF Yield % is ranked worse than
92.74% of 1556 companies
in the Biotechnology industry
Industry Median: -14.17 vs KA: -255.86

Kineta's FCF Margin % for the quarter that ended in Dec. 2023 was 0.00%.

Kineta FCF Yield % Historical Data

The historical data trend for Kineta's FCF Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kineta FCF Yield % Chart

Kineta Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

FCF Yield %

-36.16

-42.95

Kineta Quarterly Data
	Dec20	Jun21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
FCF Yield %	Get a 7-Day Free Trial						-56.75	-69.98	-110.95	-2.64	-43.19

Competitive Comparison of Kineta's FCF Yield %

For the Biotechnology subindustry, Kineta's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kineta's FCF Yield % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kineta's FCF Yield % distribution charts can be found below:

* The bar in red indicates where Kineta's FCF Yield % falls into.

Kineta FCF Yield % Calculation

FCF Yield % is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.

Kineta's FCF Yield % for the fiscal year that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	/	Market Cap
	=	-16.209	/	37.74111
	=	-42.95%

Kineta's annualized FCF Yield % for the quarter that ended in Dec. 2023 is calculated as

FCF Yield %	=	Free Cash Flow	*	Annualized Factor	/	Market Cap
	=	-4.075	*	4	/	37.74111
	=	-43.19%

Kineta FCF Yield % Explanation

Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.

Kineta FCF Yield % Related Terms

Thank you for viewing the detailed overview of Kineta's FCF Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.

Kineta (Kineta) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kineta Inc (NAS:KA) » Definitions » FCF Yield %

Comparable Companies

Traded in Other Exchanges

J75:Germany

Address

219 Terry Avenue North, Suite 300, Seattle, WA, USA, 98109

Website

https://www.kinetabio.com

Kineta Inc is a clinical-stage biotechnology company with a mission to develop next generation immunotherapies that transform patients' lives. The company's asset is KVA12.1, a VISTA blocking immunotherapy.

Executives

Raymond J. Bartoszek	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Shawn Iadonato	director, officer: Chief Executive Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Craig W. Philips	officer: President	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Pauline Kenny	officer: General Counsel	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Keith Baker	officer: Chief Financial Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Thierry Guillaudeux	officer: Chief Scientific Officer	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Scott J. Dylla	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Marion R Foote	director	C/O KINETA, INC., 219 TERRY AVE. N., SUITE 300, SEATTLE WA 98109
Michael D Wyzga	officer: See Remarks	C/O YUMANITY, INC., 40 GUEST STREET, SUITE 4410, BOSTON MA 02135
Devin Whittemore Smith	officer: SVP and General Counsel	C/O MINERVA NEUROSCIENCES, INC., 1601 TRAPELO ROAD, SUITE 286, WALTHAM MA 02451
Kimberlee C Drapkin	director	PREDIX PHARMACEUTICALS HOLDINGS, INC., 4 MAGUIRE ROAD, LEXINGTON MA 02421
Ajay Verma	officer: EVP, Head of R&D	C/O CODIAK BIOSCIENCES, INC., 35 CAMBRIDGEPARK DRIVE, SUITE 500, CAMBRIDGE MA 02140
Lynne Zydowsky	director	C/O YUMANITY THERAPEUTICS, INC., 40 GUEST STREET, BOSTON MA 02135
Susan L. Lindquist Exempt Marital Trust	10 percent owner	C/O NANCY E. DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109
Susan L. Lindquist Massachusetts Non-exempt Marital Trust	10 percent owner	C/O NANCY DEMPZE, HEMENWAY & BARNES, LLP, 75 STATE STREET, BOSTON MA 02109